Today: 29 January 2026
Subscribe
Browse Category

Pharma Industry News 30 November 2025 - 11 December 2025

GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

On 11 December 2025, outgoing GSK chief executive Dame Emma Walmsley sent a stark message to Westminster and the City: for big drug makers, the United States is now the premier destination for investment – and Britain is at risk of slipping further behind. In a broadcast interview, Walmsley praised the US as the world’s most attractive market for new…
11 December 2025
···
Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk A/S – the Danish maker of Ozempic and Wegovy – is having the kind of year investors usually wake up from, not live through. On 11 December 2025, Novo Nordisk’s U.S.-listed ADRs (ticker NVO) trade around $49 per share, after a bounce of roughly 5–6% in recent sessions. Copenhagen-listed B‑shares sit near 316 DKK, yet they remain close…
11 December 2025
····
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax Société Anonyme (Euronext Paris: ABVX, Nasdaq: ABVX) is back in the spotlight on December 10, 2025, after its share price spiked again on fresh takeover speculation involving U.S. pharma giant Eli Lilly. The move caps an extraordinary year in which the French biotech has transformed from a relatively obscure name into a multibillion‑euro inflammatory bowel disease (IBD) contender. Reuters…
10 December 2025
····
Eli Lilly Stock After Hours on December 9, 2025: 9‑Day Slide, $6B Alabama Bet and What to Watch Before the December 10 Open

Eli Lilly Stock After Hours on December 9, 2025: 9‑Day Slide, $6B Alabama Bet and What to Watch Before the December 10 Open

Eli Lilly and Company (NYSE: LLY) closed lower again on Tuesday, December 9, extending a rare nine‑session losing streak even as the drugmaker announced a multibillion‑dollar U.S. manufacturing expansion and positive cancer‑drug trial data. StockAnalysis Heading into the U.S. stock market open on Wednesday, December 10, Eli Lilly stock is showing signs of a bounce in pre‑market trading – but…
10 December 2025
····
Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson stock (NYSE: JNJ) has quietly turned into one of 2025’s standout blue‑chip winners. As of December 9, 2025, JNJ trades around $202 per share, valuing the company at roughly $486 billion and leaving the stock up close to 40% year to date. Trefis That move reflects more than just a defensive bid for a safe dividend name.…
9 December 2025
····
Eli Lilly (LLY) Stock on December 8, 2025: China Insurance Win, Trillion‑Dollar Status and What Comes Next for Investors

Eli Lilly (LLY) Stock on December 8, 2025: China Insurance Win, Trillion‑Dollar Status and What Comes Next for Investors

Updated: December 8, 2025 – For informational purposes only, not investment advice. Key takeaways 1. Where Eli Lilly (LLY) stands on December 8, 2025 As U.S. markets trade on Monday, Eli Lilly and Company (NYSE: LLY) is changing hands near $1,010 per share, roughly flat versus Friday’s close around $1,010.31 and modestly below late‑November highs near $1,110. TechStock² The recent…
8 December 2025
····
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Data and news current as of 7 December 2025. NVAX stock price now: where Novavax stands in December 2025 Novavax, Inc. (NASDAQ: NVAX) closed on Friday, 5 December 2025 at $6.91 per share, giving the vaccine maker a market value of around $1.1 billion. Novavax Investor Relations Over the last year, NVAX has slipped roughly 20%, according to data from…
7 December 2025
····
Sun Pharma Advanced Research (SPARC) Stock Soars After US Court Ruling on Sezaby PRV – What the 30% Two‑Day Rally on 3 December 2025 Really Means

Sun Pharma Advanced Research (SPARC) Stock Soars After US Court Ruling on Sezaby PRV – What the 30% Two‑Day Rally on 3 December 2025 Really Means

SPARC stock on 3 December 2025: Still volatile after a 2‑day surge Sun Pharma Advanced Research Company Ltd (SPARC) has exploded back onto traders’ screens this week. On 2 December 2025, the stock hit the 20% upper circuit at around ₹161.10, after a US court delivered a favourable ruling in a long‑running dispute over a Priority Review Voucher (PRV) linked…
3 December 2025
···
AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook

AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook

AbbVie Inc. (NYSE: ABBV) heads into the final month of 2025 as one of the most closely watched large‑cap healthcare stocks, with fresh dividend news, new oncology and migraine data, and an upbeat earnings outlook all hitting the tape just as investors look toward 2026. As of December 2, 2025, AbbVie shares trade around $224–$225 per share, giving the company…
2 December 2025
····
Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

As of late trading on Tuesday, December 2, 2025, Pfizer (NYSE: PFE) shares change hands around $25.10, down roughly 0.7% on the day and sitting in the middle of their 52‑week range of $20.92–$27.69. Yahoo Finance The stock carries a dividend yield close to 7%, reflecting a generous payout but also lingering skepticism about the pharma giant’s growth post‑COVID. Pfizer Today’s price is…
2 December 2025
····
Johnson & Johnson (JNJ) Stock News & Forecast: EU Drug Approval, $3B Cancer Deal and Dividend Strength – December 1, 2025

Johnson & Johnson (JNJ) Stock News & Forecast: EU Drug Approval, $3B Cancer Deal and Dividend Strength – December 1, 2025

As of December 1, 2025. This article is for information only and is not investment advice. JNJ stock today: riding near record highs after a huge 2025 rally Johnson & Johnson (NYSE: JNJ) stock is trading close to its 52‑week high around the low‑$200s per share, giving the healthcare giant a market capitalization of roughly $500–505 billion. PortfoliosLab Over the…
1 December 2025
····
Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Updated November 30, 2025 Pfizer stock is in the middle of a big reset. The COVID windfall is fading, but a massive obesity-drug acquisition, a landmark bladder‑cancer approval and a high dividend yield are reshaping the story investors see in PFE. Pfizer stock price today: valuation snapshot As of the last trading session on Friday, November 28, Pfizer Inc. (NYSE:…
30 November 2025
····
1 … 3 4 5 6 7 8

Stock Market Today

  • Is Clorox (CLX) Undervalued After Mixed Share Performance?
    January 29, 2026, 2:36 AM EST. Clorox's share price shows a mixed outlook, falling 1.6% in the past week but gaining 9.6% over 30 days and 7.9% year-to-date, while dropping 28.2% over one year. A discounted cash flow (DCF) analysis values Clorox at $213.36 per share, nearly 49% above the current $108.80 price, suggesting undervaluation. The company trades at a price-to-earnings (P/E) ratio of 16.8, below the Household Products sector average of 17.2 and industry peers at 21.9, highlighting market caution. Investors are reassessing consumer staples stocks amid concerns over earnings quality and resilience. Clorox receives a middling 4 out of 6 valuation score, reflecting uncertainty but potential value for long-term investors.
Go toTop